drugset / Trial / NCT07058779

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

NCT07058779 ↗

Phase 1 Recruiting 26 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedSequentialQuadruple-blindOther

Summary

This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.

Timeline

Start
2025-08-04
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SSS55 Unknown — —

Indications

No indication recorded.